黄嘌呤氧化酶抑制研究进展:潜在生物活性合成化合物综述

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Giorgio Antoniolli, Gabriel Rodrigues de Moraes, Rafael Porreca Neves da Costa, Giovani Augusto Rosendo de Campos, Fernando Coelho
{"title":"黄嘌呤氧化酶抑制研究进展:潜在生物活性合成化合物综述","authors":"Giorgio Antoniolli,&nbsp;Gabriel Rodrigues de Moraes,&nbsp;Rafael Porreca Neves da Costa,&nbsp;Giovani Augusto Rosendo de Campos,&nbsp;Fernando Coelho","doi":"10.1002/ardp.70079","DOIUrl":null,"url":null,"abstract":"<p>Hyperuricemia and gout are conditions that continue to present significant therapeutic challenges, mainly due to limitations of current treatments which may cause adverse effects such as hypersensitivity, hepatotoxicity, and cardiovascular risks. Additionally, the development of new drugs faces obstacles including toxicity, low bioavailability, and potential drug interactions. In this context, the search for new synthetic xanthine oxidase inhibitors is essential to improve treatment efficacy, selectivity, and safety. New molecules can not only prolong the duration of therapeutic effects but also minimize adverse reactions. Moreover, several compounds under investigation exhibit additional pharmacological activities, such as anti-inflammatory, antioxidant, anticholinesterase, and anticancer properties. Recent research trends also include the use of artificial intelligence, computational modeling, and the exploration of natural products—such as flavonoids and alkaloids—as sources of inspiration for new synthetic inhibitors. Furthermore, strategies like combination therapies are being explored to enhance uric acid excretion. This review conducted a systematic search for new xanthine oxidase inhibitors (2025–2020), focusing on high-impact publications and organizing the compounds according to their molecular scaffolds (number of rings). This review highlights recent advances in the development of synthetic xanthine oxidase inhibitors, emphasizing their structural diversity and the continuous relevance of this study area. The discovery of new drug candidates has the potential to provide more effective and safer therapeutic options for patients in the near future.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70079","citationCount":"0","resultStr":"{\"title\":\"Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds\",\"authors\":\"Giorgio Antoniolli,&nbsp;Gabriel Rodrigues de Moraes,&nbsp;Rafael Porreca Neves da Costa,&nbsp;Giovani Augusto Rosendo de Campos,&nbsp;Fernando Coelho\",\"doi\":\"10.1002/ardp.70079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Hyperuricemia and gout are conditions that continue to present significant therapeutic challenges, mainly due to limitations of current treatments which may cause adverse effects such as hypersensitivity, hepatotoxicity, and cardiovascular risks. Additionally, the development of new drugs faces obstacles including toxicity, low bioavailability, and potential drug interactions. In this context, the search for new synthetic xanthine oxidase inhibitors is essential to improve treatment efficacy, selectivity, and safety. New molecules can not only prolong the duration of therapeutic effects but also minimize adverse reactions. Moreover, several compounds under investigation exhibit additional pharmacological activities, such as anti-inflammatory, antioxidant, anticholinesterase, and anticancer properties. Recent research trends also include the use of artificial intelligence, computational modeling, and the exploration of natural products—such as flavonoids and alkaloids—as sources of inspiration for new synthetic inhibitors. Furthermore, strategies like combination therapies are being explored to enhance uric acid excretion. This review conducted a systematic search for new xanthine oxidase inhibitors (2025–2020), focusing on high-impact publications and organizing the compounds according to their molecular scaffolds (number of rings). This review highlights recent advances in the development of synthetic xanthine oxidase inhibitors, emphasizing their structural diversity and the continuous relevance of this study area. The discovery of new drug candidates has the potential to provide more effective and safer therapeutic options for patients in the near future.</p>\",\"PeriodicalId\":128,\"journal\":{\"name\":\"Archiv der Pharmazie\",\"volume\":\"358 8\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70079\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archiv der Pharmazie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70079\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70079","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

高尿酸血症和痛风是持续存在重大治疗挑战的疾病,主要是由于当前治疗方法的局限性,可能导致过敏、肝毒性和心血管风险等不良反应。此外,新药物的开发面临着包括毒性、低生物利用度和潜在的药物相互作用在内的障碍。在这种情况下,寻找新的合成黄嘌呤氧化酶抑制剂对于提高治疗效果、选择性和安全性至关重要。新分子不仅可以延长治疗效果的持续时间,而且可以减少不良反应。此外,一些正在研究的化合物表现出额外的药理活性,如抗炎、抗氧化、抗胆碱酯酶和抗癌特性。最近的研究趋势还包括使用人工智能、计算建模和探索天然产物——如类黄酮和生物碱——作为新的合成抑制剂的灵感来源。此外,正在探索诸如联合治疗之类的策略来增强尿酸排泄。本综述对新的黄嘌呤氧化酶抑制剂(2025-2020)进行了系统搜索,重点关注高影响力的出版物,并根据其分子支架(环数)对化合物进行组织。本文综述了近年来合成黄嘌呤氧化酶抑制剂的研究进展,强调了它们的结构多样性和本研究领域的持续相关性。新的候选药物的发现有可能在不久的将来为患者提供更有效和更安全的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds

Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds

Hyperuricemia and gout are conditions that continue to present significant therapeutic challenges, mainly due to limitations of current treatments which may cause adverse effects such as hypersensitivity, hepatotoxicity, and cardiovascular risks. Additionally, the development of new drugs faces obstacles including toxicity, low bioavailability, and potential drug interactions. In this context, the search for new synthetic xanthine oxidase inhibitors is essential to improve treatment efficacy, selectivity, and safety. New molecules can not only prolong the duration of therapeutic effects but also minimize adverse reactions. Moreover, several compounds under investigation exhibit additional pharmacological activities, such as anti-inflammatory, antioxidant, anticholinesterase, and anticancer properties. Recent research trends also include the use of artificial intelligence, computational modeling, and the exploration of natural products—such as flavonoids and alkaloids—as sources of inspiration for new synthetic inhibitors. Furthermore, strategies like combination therapies are being explored to enhance uric acid excretion. This review conducted a systematic search for new xanthine oxidase inhibitors (2025–2020), focusing on high-impact publications and organizing the compounds according to their molecular scaffolds (number of rings). This review highlights recent advances in the development of synthetic xanthine oxidase inhibitors, emphasizing their structural diversity and the continuous relevance of this study area. The discovery of new drug candidates has the potential to provide more effective and safer therapeutic options for patients in the near future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信